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Summary
Owing to the rapid turnaround time in the assessment of
haemoglobin level by point-of-care tests (POC Hb), these
have grown in popularity and scope in large parts of the
world. However, whilst POC testing for malaria and HIV
remains has been integrated into patient management in
Africa, the use of POC haemoglobin testing remains
neglected by health services. The main users of transfusions
(paediatric, maternity and trauma services) present largely as
emergencies. Ward-based POC Hb could result in more
rapid and accurate diagnosis of anaemia, contributing to sav-
ing of lives and at the same time reduce unnecessary transfu-
sions which deplete the limited supplies of donated blood in
Africa. Severe anaemia requiring transfusion is a major cause
of paediatric admission in Africa. At a dissemination meeting
to discuss the results of a large phase III paediatric transfu-
sion trial and steps to implementation of the findings partici-
pants strongly recommended that one of the most pressing
actions required was to prioritise the use of POC haemoglo-
bin testing. This would facilitate implementation of the new
transfusion algorithm, developed at the meeting, which
refines patient management including blood transfusions. We
present the rationale for the strongly recommended prioriti-
sation of POC Hb, using paediatric transfusion as an exem-
plar.
Keywords: anaemia in developing world, diagnostic haema-
tology, transfusion medicine, paediatric anaemia, children.
In many countries in sub-Saharan Africa, in stark contrast
to other areas of the world, children are the main
recipients of blood transfusions, where severe anaemia
[haemoglobin (Hb) <60 g/l] remains a leading cause of
both admission to hospital and of direct mortality.1-4
Owing to limited supplies of donated blood, the World
Health Organization (WHO) guidelines encourage restric-
tive transfusion approaches. Specifically, these conservative
strategies recommend not transfusing children with uncom-
plicated anaemia (haemoglobin of 40–60 g/l).5 However,
the evidence informing these recommendations was previ-
ously weak and thus adherence was poor. Delays in the
provision of an emergency transfusion in children are
common, with early fatalities occurring in children await-
ing a transfusion.6,7
In 2019, a large multicentre phase III trial (TRACT)
enrolling 3 983 children with severe anaemia in four hospi-
tals in Uganda and Malawi provided high-quality evidence
to support and refine current treatment guidelines.8,9
Within the trial, 1 565 children with uncomplicated severe
anaemia (haemoglobin 40–60 g/l and no severity features)
were randomised to immediate (experimental) versus no
immediate transfusions (control: WHO standard of care).
In this stratum an initial (for control) or additional trans-
fusions were permitted if prompted or ‘triggered’ by the
development of new severity signs or post-randomisation
haemoglobin <40 g/l. Overall, the TRACT trial found no
evidence of differences in 28-day mortality, 180-day mortal-
ity or readmissions between immediate and triggered trans-
fusion strategies. Nevertheless, for children in the control
arm who followed WHO guidelines (no immediate transfu-
sion), 49% went on to develop severe and complicated
anaemia — a clinical scenario that the current guideline
does not anticipate. Among those developing severe criteria,
in 76% this was diagnosed as a subsequent measurement of
haemoglobin that was below 40 g/l (profound anaemia),
and in 15% it was due to the development of a new clini-
cal severity sign. As a result this ‘triggered’ the requirement
for a blood transfusion. Whilst this was possible in a clini-
cal trial that included frequent monitoring of haemoglobin,
Correspondence: Kathryn Maitland, Imperial College, London, UK.
E-mail: k.maitland@imperial.ac.uk
good practice papers
ª 2021 The Authors. British Journal of Haematology published by British Society for Haematology and
John Wiley & Sons Ltd
This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any
medium, provided the original work is properly cited.
doi: 10.1111/bjh.17431
in reality this relatively simple task remains an insurmount-
able problem since point-of-care (POC) diagnostics and
access to round-the-clock laboratory services to provide
blood counts are lacking in most settings where these chil-
dren are cared for.
Nevertheless, if this potential barrier for blood transfu-
sions services would be addressed, and if the results of the
trial were adopted, a triggered transfusion strategy would
reduce blood requirements in the group of children with
uncomplicated severe anaemia by ~60% compared to
immediate transfusion, thus preserving blood transfusion
supplies for emergencies. This finding is important in set-
tings like those where the TRACT trial was conducted,
where shortages of donor blood are still frequent,10 despite
a decade or more of increased external aid to support
blood transfusion services.11 Moreover, a triggered transfu-
sion strategy is considerably less costly for the health ser-
vices than immediate transfusions despite the longer length
of stay in hospital (around 24 h, on average).8 Overall, 28-
day mortality (<2%) was substantially lower than expected
to which a number of factors may have contributed, includ-
ing closer clinical surveillance and repeated haemoglobin
monitoring, so that those developing severe and compli-
cated anaemia were rapidly identified and provided with
transfusions.
Translating the results into clinical practice first needs a
careful consideration of potential barriers to implementation
and what might be needed to support safe implementation
of the TRACT findings.
Dissemination meeting
A meeting in Kampala, Uganda in February 2020 that was
co-hosted by the African Society for Blood Transfusion
(AfSBT) and the Uganda Paediatric Association brought
together representatives from across the relevant regions in
sub-Saharan Africa: blood transfusion services, health ser-
vice providers (paediatricians involved in providing contin-
ued professional development and training courses) and
representatives from international policymakers (Medecins
Sans Frontieres and the Ugandan representative for WHO).
The aims were to clarify what current practices are in dif-
ferent settings within Africa, to explore the findings of the
TRACT trial and implications from their own perspectives,
to identify potential barriers to implementing the TRACT
findings, and what might be needed to support safe imple-
mentation of the TRACT findings. Finally, the last aim
was to develop a package of interventions (which might
include training tools, job aids and revised processes) for
subsequent implementation research. Here we specifically
report on the aspect that was agreed to be a major barrier
to effective implementation: timely access to initial and
repeated haemoglobin testing in children with suspected
severe anaemia.
Current practice
Prior to the meeting we sent out a structured survey enquir-
ing about local guidelines for management of severe anaemia
and including two specific questions on haemoglobin testing.
Most clinicians reported that their current guidelines and
practice aim to follow WHO guidelines. These guidelines
include recommendations that restrict routine transfusion to
only those with a haemoglobin less than 40 g/l (haematocrit
<12%) or 40–50 g/l if they have additional signs of severity.5
Nevertheless, the evidence base for the paediatric guidelines
is weak, which has led to confusing recommendations within
these guidelines and poor adherence.7,12 However, the guide-
lines give no specific guidance on clinical or haematological
post-admission monitoring of children to identify those chil-
dren who subsequently develop new severity criteria warrant-
ing transfusion.
We asked about the most common method used for anae-
mia diagnosis [POC Hb, haematocrit or full blood count
(haemogram)] and how long it generally took to get a hae-
moglobin/haematocrit (or haemogram) result. Most indi-
cated it would take between 1 and 8 h and 10% indicated
the following day. Haemoglobin testing was only reliably
available in just under 40% of those facilities. A recent publi-
cation on transfusion practice in Kenyan hospitals showed
that, after adjusting for such features as severe illness, chil-
dren for whom a transfusion was ordered and given on the
same day had lower mortality [Odds Ratio (OR) = 058,
95% confidence interval (CI) = 038–087] than those whose
transfusion was delayed (≥ 1 day after prescription).6 Chil-
dren in whom transfusion was ordered but was never
received had a substantially higher in-hospital mortality: 20%
vs 12% in those receiving blood (OR = 18, 95% CI = 13–
249).6 Although there may have been other reasons for the
worse outcome in those not receiving a transfusion in this
study, we have previously shown that many severely anaemic
children (<50 g/l) that could not be transfused in the first
8 h (owing to stocks out at the blood bank) a significant
proportion died [54/103 (52%)]; 90% of these deaths
occurred within 25 h of Hb measurement and 100% had
died within 5 h of this timepoint.7 We therefore conclude
that delays in receipt of blood for transfusion are costing
lives in those that need it most. The paediatricians involved
in national guideline training who attended the meeting were
concerned that adherence to the new algorithm would be dif-
ficult unless there is a greater focus on getting POC Hb tests
onto the hospital wards, as has been done for malaria and
HIV, but not for anaemia.
In the TRACT trial, point-of-care (POC) Hb was avail-
able to test any child with suspected severe anaemia (severe
pallor), largely taken at hospital admission. The time
between screening, enrolment and receipt of the first trans-
fusion was on average 1 h,8 which may have accounted for
the overall low mortality rate. One other factor that could
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explain the lower mortality was suspending trial recruitment
when donor blood was not available. Despite the strength-
ening of hospital laboratories, there is substantial evidence
that many prescriptions of blood for paediatric transfusion
are not supported by a Hb test.13 It has been reported that
up to 45–65% of paediatric transfusion requests were not
based on the result of a Hb reading but on the clinical
judgement of the treating physician.6,12 In this regard, the
clinical indicator clinicians frequently use to guide manage-
ment is the presence of severe pallor. However, this has
been shown to have a low specificity for accurately identify-
ing severe anaemia (Hb < 50 g/l).14 In a subanalysis of a
trial recruiting children with impaired perfusion, 381/501
(77%) of children with Hb 50–70 g/l (moderate anaemia)
and 167/843 (20%) who had Hb 70–100 g/l (mild anaemia)
had clinician-recorded severe pallor on clinical examina-
tion.7 Thus, the clinical utility of pallor as a screening test
for suspected anaemia therefore seems more relevant to
community assessment and pre-referral.15,16
Point-of-care haemoglobin testing
Despite the recognition by WHO that cheap and reliable
measures of haemoglobin are an important tool for health
services, such assays have not been prioritised in countries
where there is the greatest need.17 For example, those
designed for other parts of the world have lower limits of
detection at Hb ~70–80 g/l.18,19 Although a relatively small
number have been developed and evaluated for low resource
settings20–23 in reality none have become more widely uti-
lized or adopted. Moreover, some are only optimised for
reading Hb >40 g/l20,21 or have been repurposed in experi-
mental research conditions but are currently not available on
the market.23 EKF Diagnostics (Cardiff, UK) have recently
released the DiaSpect TM, a handheld device with a measure-
ment range of 0–255 g/l, with a Bluetooth interface which is
yet to be tested in children with severe anaemia (https://
www.ekfdiagnostics.com/diaspect.html).
Point-of-care haemoglobin testing in the TRACT
trial
At the time the TRACT trial was conducted there were few
options for reliable and validated technologies for the mea-
surement of Hb, especially in the range of haemoglobins
antipicated in children hospitalized with severe anaemia. We
opted to use the HemoCue Hb 301 system (HemoCue AB,
Angelholm, Sweden) which is a portable POC Hb testing kit,
factory-calibrated against the reference method (without
requirement for recalibration) and requiring virtually no
maintenance. Disposable microcuvettes use microsamples of
capillary or venous blood samples. The measurement range is
0 to 256 g/l, with results that are available in 10 s. Blood-
based liquid controls were used for between-batch
(microcuvettes) testing. It was selected based on its speed,
reasonable cost and previous validation in relevant popula-
tions.16,24
Point-of-care haemoglobin testing: was it
reliable even in children with profound
anaemia?
Whilst the HemoCue was used to obtain a haemoglobin at
screening, baseline blood sampling included a full blood
count (haemogram) which was taken straight after
cassent/consent and before the start of any transfusion (per
protocol). In 3 856/3 983 (97%) patients we were able to
compare haemoglobin measurements using both of these
methods (Fig 1). The median time from randomisation to
the sample being taken was 9 min [interquartile range (IQR)
5–15 min]. Overall, 96% of haemograms were taken after
randomisation and within 3 h, with 131 (3%) samples being
taken before randomisation. For the analysis, we excluded
haemogram-derived Hb taken >2 h from randomisation
(n = 59) to ensure sampling was prior to starting any trans-
fusion. The mean difference between Hb from HemoCue
and Hb from a haemogram was very small (0046;
P = 002 from a one-sample two-sided t-test) — a difference
that is not clinically relevant. As such there was no indication
of a systematic over- or underestimation of haemoglobin.
The agreement between the two methods was compared by
Lin’s concordance statistic [061 (95% CI 059–063)] and
was fair. There were some outliers (26 had Hb levels >100 g/
l) which were due to errors in following the laboratory stan-
dard operating procedure (SOP), where blood had sedi-
mented in samples that were not agitated before running the
haemogram. In summary, we can be confident that POC Hb
(HemoCue) performed well in a population with suspected
severe anaemia and if implemented would result in savings
across the health services if blood transfusion services
Fig 1. Comparison of haemoglobin measurements by Hemocue and
haemogram. [Colour figure can be viewed at wileyonlinelibrary.com]
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required that a transfusion could only be ordered if sup-
ported by a Hb test.
Alternative methods of estimating
haemoglobin
Haematocrit
Measurement of haematocrit count is easy, cheap and can be
performed in most rural hospitals.
Haemoglobin is then generally estimated from haematocrit
(Hct) using a conversion factor of Hct = 3 9 Hb. Thus sev-
ere anaemia (Hb < 60 g/l) would equate to a Hct level of
<18% and profound anaemia (Hb < 40 g/l) to a Hct level of
<12%. We note that a number of investigators have reported
that this conversion factor/estimation is not very accu-
rate.25,26 This includes a community study conducted in
healthy children in Tanzania and Mozambique demonstrat-
ing a prevalence of mild (80–110 g/l) and moderate anaemia
(<80 g/l) which were 74% and 10%, respectively, when
defined by Hb but the rates were lower if defined by Hct
(42% and 3% respectively). This implies 72% (206/287) of
the samples classified by Hb levels as moderate anaemia were
not detected using Hct levels.25 Others have suggested using
a lower conversion factor of 26;27 however, in practice this
would be more difficult to calculate and impractical to
inform immediate patient management by most health work-
ers.
Assessing the accuracy of haematocrit for
identifying children with severe anaemia
Haematocrit is a parameter included in a haemogram, so we
were able to compare haemoglobin from the HemoCue to
haemoglobin calculated from the haematocrit (using the con-
version factor of HCT = 3 9 Hb). The analysis was
restricted to those with haematocrit measured from a haemo-
gram taken within 2 h of randomisation [n = 3 855/3 983
(97%)]. This showed a poorer degree of agreement with a
mean difference of 3 g/l between the two methods
(P < 00001 one-sample two-sided t-test; Fig 2). Lin’s con-
cordance coefficient was 054 (95% CI 052, 056) indicating
the proxy estimation of Hb using haematocrit was worse
than using Hb from a haemogram.
We also considered the specificity and sensitivity of using
haematocrit cut-offs instead of HemoCue cut-offs for defini-
tions of profound or severe anaemia, since these are often
used by health services as ward-based tests. A 12% haemat-
ocrit cut-off is generally used to estimate profound anaemia
(Hb < 40 g/l); we found this gave a sensitivity of 88% and
specificity of 78%. An 18% haematocrit cut-off to estimate
severe anaemia (Hb < 60 g/l) had a sensitivity of 83%.
However, we were unable to calculate the specificity since
all eligible children in the trial had a Hb < 60 g/l on the
POC Hb result. In conclusion, using data from the TRACT
trial, we showed that haematocrit provided a reasonable
alternative as a method for detecting anaemia. In practice,
however, there are other technical challenges in safe collec-
tion and processing of capillary blood often used for
haematocrit assessment.28
Nevertheless, the comparison does not fully address
whether ward-based tests, which in many hospitals include
results from a haematocrit machine, may be less accurate
than a haematocrit from a haemogram. In order for us to
examine this specific question, we compared haemoglobin
measured by HemoCue to estimated haemoglobin calculated
from haematocrit (from a ward-based machine) taken from
bags of donor whole blood used in the TRACT trial
(n = 2 220 packs).29 The mean difference between the two
methods was 082 (P < 00001, one-sample two-sided t-
test; Fig 3) Lin’s concordance coefficient was 072 (95% CI
070–073). The good agreement between Hb calculated from
Hct and Hb from the HemoCue is reassuring; however, the
population did not include anyone with anaemia (who are
generally screened out prior to blood donation) and there is
wide variability (SD = 303). The better concordance for
these tests in donor blood compared to haemogram and
HemoCue in children with severe anaemia may also be sim-
ply due to the lack of a restriction so both methods on
donor blood have a much wider range compared to the
methods used for the children. Further research is needed to
see if this method of Hb estimation could be introduced to
or strengthened in paediatric wards to support best transfu-
sion practice.
WHO haemoglobin colour scale
Owing to the poor specificity of pallor for assessment of
anaemia the WHO developed the haemoglobin colour scale
(HCS) as an inexpensive, simple alternative for assessing
anaemia. A systematic review examined its utility in a wide
range of settings including 14 studies, most conducted in
sub-Saharan Africa. The sensitivity of HCS was found to be
high in most of the studies (75–97%) but the specificity was
lower (41–98%) with both being higher for laboratory-based
studies compared with more pragmatic ’real-life’ studies. It
was concluded that where there is no access to laboratory a
HCS may improve anaemia diagnosis; however further prag-
matic research was recommended to help inform policy with
a focus on ease of implementation.30 In Uganda, in children
identified by health personnel (nurses and clinicians) as
severely anaemic (based on assessment of pallor) for which
they would empirically order a blood transfusion (if haemo-
globin was unknown) the WHO Hemoglobin Colour Scale
had a high specificity of 956 (907–984) but lacked sensitiv-
ity [431 (342–523)] for those with Hb < 50 g/l diagnosed
using HemoCue.14
Relevant to this question, a study conducted in Malawi
evaluated the characteristics of various manual Hb methods
for accuracy, including assessment of the WHO HCS. The
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performance was judged against a reference standard
(haemiglobincyanide method). For the HCS 95% of the
results differ by only 48% below and 37% above the refer-
ence results compared to 6% and 16% for the HemoCue.31
In addition to examining performance of each haemoglobin
method the researchers also compared a range of parameters
including clinical usefulness, user friendliness, speed, training
time and economic costs for six haemoglobin measurement
methods. The authors proposed that these could be applied
as a practical model for gathering evidence about test effi-
ciency that could be adapted for use in other resource-poor
settings. On this basis, HemoCue was found to be the ideal
in terms of ease of use, speed, minimal requirement for
training and reliability of the results; however it was the most
expensive (075 US dollars/test). The Ugandan study, con-
ducted a decade later, found the cost of the HemoCue test
had increased (~40 USD/test at 2019 prices, after an initial
cost of between 250 and 350 USD for the HemoCue analy-
ser). This was more costly than then next best test, Sahli’s
method (025 USD/test, after an initial cost of 40–50 USD
for the meter); however, Sahli’s Hb estimation requires a
functioning and accessible laboratory service14 and it is less
Fig 2. Comparison of haemoglobin estimated from haematocrit versus haemoglobin from HemoCue in children with severe anaemia. [Colour fig-
ure can be viewed at wileyonlinelibrary.com]
Fig 3. Haemoglobin estimated from haematocrit versus haemoglobin from HemoCue in Donor blood. [Colour figure can be viewed at wileyon
linelibrary.com]
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practicable for emergencies and for ‘out of hours’ admis-
sions.
TRACT trial management algorithm
To update current guidelines, with the new findings from the
TRACT trial, a consensus severe anaemia management algo-
rithm was developed with the aim of improving evidence-
based clinical practice and averting the unnecessary use of
transfusion in children with uncomplicated severe anaemia.32
However, two vital components of the transfusion manage-
ment algorithm included both clinical and Hb monitoring.
Using data from the TRACT trial, we were able to show that
a minimum of three additional measurements of Hb over
48 h of hospital stay would identify ~50% developing severe
and complicated anaemia since 76% of children required a
transfusion following of a drop in Hb < 40 g/l. From this
watch and wait policy there was no evidence of short- or
long-term adverse events (morbidity and mortality). The big-
gest concern raised at the meeting was that future evidence-
based practice would require the provision of POC Hb test-
ing — something that most hospitals do not have.
Role of point-of-care testing in patient
management
Point-of-care (POC) testing is a diagnostic procedure done
at or near the site of care and has the benefit of providing
immediate results to a clinician (and patient where neces-
sary) without having to wait hours or even days for sample
transport and laboratory processing. Practical considerations
for the POC products are that they do not rely on physical
infrastructure (including electricity, refrigeration, and/or run-
ning water or all). Increasingly, POC technology is being
introduced to doctors’ clinics to meet specific patients’ indi-
cations in developed countries.33 These types of diagnostic
platforms could also enable better approaches to low-re-
source-setting tests. To date, POC tests used in resource-lim-
ited settings have principally focused on infectious diseases
that need prompt diagnosis and treatment, such as HIV,
tuberculosis and malaria.
Point-of-care haemoglobin testing : using the
TRACT trial as an exemplar
The development and design of clinically and commercially
viable POC products for low- and middle-income countries
(LIMCs) in a reasonable time and clinical studies that show
implementation results with better patient outcomes. The lat-
ter consideration has often been difficult to prove, since imple-
mentation studies with survival as an outcome are rare. In the
TRACT trial, POC Hb was incorporated as a screening proce-
dure to identify children with severe anaemia and to inform
use of emergency interventions (in this case transfusion), thus
demonstrating its clinical utility. For emergency interventions,
this aspect is critical since it can be done at any time of the
day/night, during holidays and when there is no power — all
of which reduce the availability and speed of laboratory-based
diagnoses. Whilst mortality rates in children with uncompli-
cated anaemia were too low either to demonstrate or refute
any benefits of an immediate transfusion compared to control
(WHO standard of care), the large multicentre TRACT trial
demonstrated that in children with uncomplicated severe anae-
mia a triggered transfusion strategy was safe and cost-effective
but required clinical and Hb monitoring.
Other patient groups where point-of-care
haemoglobin testing could be useful in African
hospitals
Severe anaemia, requiring transfusion, is a very common
maternity-related complication.34 Quite often moderate to
severe anaemia arises during pregnancy, but is more critically
in the peripartum period, where between 20 and 30% of
maternal deaths in Africa are due to postpartum haemor-
rhage.35 Lack of access to blood transfusions and poorly
organised health services have been implicated in the high
maternal mortality rates in African countries. Point-of care
Hb at busy antenatal clinics to identify and treat anaemia
and in the obstetric units would facilitate improved manage-
ment since the degree of blood loss in postpartum haemor-
rhage is often underestimated.
Other emergencies which would benefit from rapid diag-
nosis of haemoglobin include the growing burden of trauma,
largely from road traffic accidents, on the continent.36
Barriers to adoption
A number of barriers currently prevent the adoption of exist-
ing, and the introduction of new diagnostics in LMICs due, in
part, to challenges posed by centralisation of laboratory sys-
tems. Whilst centralised laboratories play an important role in
providing medical diagnostic services, they require significant
infrastructure and trained personnel. The aim of POC tests is
to supplement, not replace, centralised laboratory testing, thus
bringing diagnostics to the hospital ward or bedside, enabling
timely diagnosis and leading to expedited clinical decisions. In
the case of severe anaemia for comprehensive clinical care, we
recognised that an initial POC Hb should not replace the
requirement for essential laboratory investigations (including
full blood count or haemogram) to refine diagnosis and guide
comprehensive patient management. To avoid a one size fits all
scenario, the assessment process of any diagnostic test should
take place within a specific clinical indication and with a speci-
fied purpose for the diagnostic test. Drain and colleagues pro-
posed a framework for the assessment of point-of-care tests,
and how their efficacy can be defined and evaluated in opera-
tional research that is centred on clinical decision-making.37
They refer to the WHO ASSURED criteria which outline the
ideal characteristics of a POC for resource-limited settings.
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Originally developed as a benchmark for clinical tests to iden-
tify sexually transmitted disease, they consist of the following
criteria: Affordable, Sensitive (low number of false nega-
tives), Specific (low numbers of false positives), User-friendly
(and minimal training required), Rapid and robust (i.e. does
not need refrigeration), Equipment-free and Deliverable to
those who need it.38 These criteria can equally be applied to
POC Hb, where we believe there is a strong case for advocating
for the introduction of new POC Hb diagnostics if supported
by well executed studies on diagnostic accuracy, clinical effect
and cost in a non-clinical trial context. Most published studies
of point-of-care tests in resource-limited settings have focused
on analytical performance, with few studies assessing a test’s
effects on patient-centred outcomes. Thus, assessing the impact
of using POC Hb in routine care on patient-focused outcomes
(e.g., survival) is vitally important.
Conclusions
We advocate for POC Hb to be more widely available for
hospitals across sub-Saharan Africa, so that requests for
blood transfusion are better supported by prompt, accurate
and serial Hb testing. This could have dual benefits, so that
severe and life-threatening anaemia is identified rapidly, and
cost-savings to the blood transfusion services realised, reduc-
ing the number of unwarranted prescriptions of blood for
transfusions.
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